JP2015078168A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078168A5
JP2015078168A5 JP2013235506A JP2013235506A JP2015078168A5 JP 2015078168 A5 JP2015078168 A5 JP 2015078168A5 JP 2013235506 A JP2013235506 A JP 2013235506A JP 2013235506 A JP2013235506 A JP 2013235506A JP 2015078168 A5 JP2015078168 A5 JP 2015078168A5
Authority
JP
Japan
Prior art keywords
psma
abgenix
composition
ligand
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013235506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078168A (ja
JP6908964B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to CA3181096A priority Critical patent/CA3181096A1/en
Priority to PCT/US2014/000124 priority patent/WO2015057250A1/en
Priority to ES14734570T priority patent/ES2837927T3/es
Priority to EP14734570.6A priority patent/EP3057614B1/en
Priority to EP20199101.5A priority patent/EP3827844A1/en
Priority to AU2014337391A priority patent/AU2014337391B2/en
Priority to CA2927735A priority patent/CA2927735C/en
Priority to US14/277,367 priority patent/US20150110814A1/en
Publication of JP2015078168A publication Critical patent/JP2015078168A/ja
Publication of JP2015078168A5 publication Critical patent/JP2015078168A5/ja
Priority to JP2019111139A priority patent/JP7716836B2/ja
Priority to AU2020203191A priority patent/AU2020203191B2/en
Application granted granted Critical
Publication of JP6908964B2 publication Critical patent/JP6908964B2/ja
Priority to AU2023200926A priority patent/AU2023200926A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013235506A 2013-10-18 2013-11-13 Ｐｓｍａリガンドコンジュゲートによる併用療法 Active JP6908964B2 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US14/277,367 US20150110814A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
ES14734570T ES2837927T3 (es) 2013-10-18 2014-05-14 Terapias de combinación con conjugados de ligando de PSMA
EP14734570.6A EP3057614B1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
EP20199101.5A EP3827844A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
AU2014337391A AU2014337391B2 (en) 2013-10-18 2014-05-14 Combination therapies with PSMA ligand conjugates
CA2927735A CA2927735C (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
CA3181096A CA3181096A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
PCT/US2014/000124 WO2015057250A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
JP2019111139A JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法
AU2020203191A AU2020203191B2 (en) 2013-10-18 2020-05-15 Combination therapies with psma ligand conjugates
AU2023200926A AU2023200926A1 (en) 2013-10-18 2023-02-17 Combination therapies with psma ligand conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361893145P 2013-10-18 2013-10-18
US61/893,145 2013-10-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019111139A Division JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法

Publications (3)

Publication Number Publication Date
JP2015078168A JP2015078168A (ja) 2015-04-23
JP2015078168A5 true JP2015078168A5 (https=) 2017-07-20
JP6908964B2 JP6908964B2 (ja) 2021-07-28

Family

ID=53009949

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013235506A Active JP6908964B2 (ja) 2013-10-18 2013-11-13 Ｐｓｍａリガンドコンジュゲートによる併用療法
JP2019111139A Active JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法
JP2023076905A Pending JP2023135666A (ja) 2013-10-18 2023-05-08 Ｐｓｍａリガンドコンジュゲートによる併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019111139A Active JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法
JP2023076905A Pending JP2023135666A (ja) 2013-10-18 2023-05-08 Ｐｓｍａリガンドコンジュゲートによる併用療法

Country Status (4)

Country Link
EP (2) EP3827844A1 (https=)
JP (3) JP6908964B2 (https=)
AU (3) AU2014337391B2 (https=)
CA (2) CA2927735C (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
EP4344747A3 (en) * 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
WO2020077259A1 (en) * 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Combination therapy for treating metastatic prostate cancer
CN119792549A (zh) * 2021-04-23 2025-04-11 天津全和诚生物技术有限公司 缀合物及其制备方法和用途
WO2025125469A1 (en) * 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用
WO2025216238A1 (ja) * 2024-04-09 2025-10-16 国立大学法人広島大学 薬物コンジュゲート又はその塩

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
EP2326350B1 (en) * 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
AU2010260195B2 (en) 2009-06-15 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US20140099257A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability

Similar Documents

Publication Publication Date Title
JP2015078168A5 (https=)
JP2019194209A5 (https=)
JP7354079B2 (ja) 尿路の新生物の治療における使用のための多重特異性抗体
JP2009197002A5 (https=)
JP6426607B2 (ja) １５８ｐ１ｄ７タンパク質に結合する抗体薬物結合体（ａｄｃ）
JP2010513303A5 (https=)
JP2015523961A5 (https=)
JP2011524421A5 (https=)
JP2009506790A5 (https=)
JP2017507936A5 (https=)
JP2018534933A5 (https=)
JP2015534577A5 (https=)
JP2014502957A5 (https=)
RU2010130993A (ru) Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
RU2016141267A (ru) Антитела против egfr и конъюгаты антитело-лекарственное средство
JP2014522850A5 (https=)
AR069979A1 (es) Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
JP2013227339A5 (https=)
WO2008010101A3 (en) Antagonist antibody against epha2 for the treatment of cancer
CN102448486A (zh) 结合于24p4c12蛋白的抗体药物偶联物(adc)
WO2011159847A3 (en) Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
JP2017522861A5 (https=)
JP2014509835A5 (https=)
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
JP2016523810A5 (https=)